At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 187 enrolled
Drug / intervention
gemcitabine +2 moredrug
Likely dose
gemcitabine 1500 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Trial of Paclitaxel and Bevacizumab Versus Gemcitabine, Paclitaxel, and Bevacizumab as First Line Treatment for Locally Advanced or Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating gemcitabine, paclitaxel, and 1 other intervention for Breast Cancer. Completed, enrolled 187 participants across 32 sites in 2 countries.
Detailed Summary
This study will compare the cancer response to both treatments for locally advanced or metastatic breast cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesPuerto Rico, United States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
First PostedMay 2006
Primary CompletionApr 2009
Study CompletionAug 2012
TodayJul 2026
First PostedMay 3, 2006
Enrollment StartMay 1, 2006
Primary CompletionApr 1, 2009
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 20.2 years ago
Interventions
gemcitabinedrug
1500 mg/m2, IV day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
paclitaxeldrug
90 mg/m2, IV, day 1, day 8 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
bevacizumabdrug
10 mg/kg, IV, day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity